LTRNLantern Pharma Inc
LTRN
Lantern Pharma Inc1,532
Mkt Cap
$15.42MVolume
1.26M52W High
$5.7452W Low
$1.11PE Ratio
-0.90LTRN Fundamentals
Price
$1.42Prev Close
$1.37Open
$1.5050D MA
$2.62Beta
1.81Avg. Volume
1.22MEPS (Annual)
-$1.57P/B
2.45Rev/Employee
$0.00$22.98
AI and Biotech Enter a Stock Picker’s Market
The market is sending a mixed but telling signal: innovation is accelerating, but only the most disciplined and well-positioned companies are keeping pace. Across AI, biotech, and micro-cap tech, recent developments highlight a widening divide between firms gaining validation and those fighting to maintain footing in public markets. $BFRG, $TGNT, $LTRN, $VRAX, $KIDZ, $HKIT
24-7 Market News·2d ago
Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging its proprietary RADR artificial intelligence (AI) and machine learning (ML) platform to transform the cost...
Business Wire·2d ago
Why Is Lantern Pharma Stock Soaring Monday?
Lantern Pharma shares rebound in premarket trading as the company debunks a false report regarding CEO Panna Sharma's departure.read more...
Benzinga·3d ago
Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report
Lantern Pharma Inc. (NASDAQ: LTRN) (Lantern or the Company), an AIdriven, clinicalstage oncology company leveraging its proprietary RADR platform to transform the cost and timeline of cancer drug development, today issued the following statement in response to an article published earlier today on...
Business Wire·5d ago
Lantern Pharma Stock Falls 10% After FDA Clears Investigational New Drug Application For STAR-001
(RTTNews) - Stock of Lantern Pharma Inc. (LTRN) is moving down about 10 percent on Friday morning trading after the company, along with its subsidiary Starlight Therapeutics, announced that the U.S. Food and Drug Administration has cleared the Investigational New Drug application...
Nasdaq News: Markets·6d ago
AI, Biotech, and Biologics Drive Big Narratives
A new wave of healthcare innovation, powered by artificial intelligence, next-generation biologics, and shifting regulatory pathways, is colliding with market dynamics to create both breakthrough potential and high-volatility trading setups. $ARTL, $TGNT, $ADMA, $RCKT, $LTRN, $GCTK
24-7 Market News·6d ago
Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001
Lantern Pharma Inc. (NASDAQ: LTRN) and its CNS-oncology focused wholly owned subsidiary Starlight Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared the...
Business Wire·6d ago
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform...
Business Wire·9d ago
<
1
2
...
>